

IDEXX LABORATORIES INC /DE
Form 4
January 11, 2013

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
RAINES MERILEE

2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE
[IDXX]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)
ONE IDEXX DRIVE
(Street)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2013

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
Executive VP & CFO

WESTBROOK, ME 04092

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2013		M		2,032	A	\$ 38.335
Common Stock	01/09/2013		M		5,694	A	\$ 17.135
Common Stock	01/09/2013		S ⁽¹⁾		3,226	D	\$ 97.51 ⁽²⁾
Common Stock	01/09/2013		S ⁽¹⁾		4,500	D	\$ 96.92 ⁽³⁾
Common Stock							13,430
						I	By Charitable Remainder

Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Security (Instr. 3 and 4)	Amount or Number of Shares
						Date Exercisable	Expiration Date		
						Title			
Non-Qualified Stock Option (right to buy)	\$ 38.335	01/09/2013		M	2,032	(4)	02/13/2013	Common Stock	2,032
Non-Qualified Stock Option (right to buy)	\$ 17.135	01/09/2013		M	5,694	(5)	02/06/2013	Common Stock	5,694

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
RAINES MERILEE ONE IDEXX DRIVE WESTBROOK, ME 04092			Executive VP & CFO	

Signatures

Conan R. Dedy, Attorney-in-Fact for Merilee Raines

01/11/2013

____ Signature of Reporting Person

____ Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Edgar Filing: IDEXX LABORATORIES INC /DE - Form 4

- (1) The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 04/26/2012.
The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$97.27 to \$97.85, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder
- (2) of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 to this Form 4.
- (3) The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from \$96.27 to \$97.26, inclusive.
- (4) Grant of options to buy shares of common stock becomes exercisable as to 2,960 shares on 02/14/2007, 02/14/2008, 02/14/2009, 02/14/2010, and the remaining 352 shares on 02/14/2011.
- (5) Grant of options to buy shares of common stock becomes exercisable as to 8,000 shares on 02/06/2004, 02/06/2005, 02/06/2006, 02/06/2007, and the remaining 2,164 shares on 02/06/2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.